Two phase III trials of bimekizumab for the treatment of moderate-to-severe hidradenitis suppurativa: a critically appraised research paper
This article presents a critical appraisal of ‘Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE-HEARD I and BE-HEARD II): two 48-week, randomized, double-blind, placebo-controlled, multicentre phase III trials’.
Authors
- Hans Christian Ring
- Rebecca McCarthy
Institutions
- Queen Mary University of London (GB)
- Barts Health NHS Trust (GB)
- Royal London Hospital (GB)
- Zealand University Hospital (DK)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1093/bjd/ljag051
- Primary Topic
- Hidradenitis Suppurativa and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00